58559-52-7

Upstream product

• 6274-24-4 (3-amino-phenoxy)-acetic acid 
• 64-17-5 ethanol 
• 5544-77-4 2-(3-nitrophenoxy)-acetic acid ethyl ester 
• 1878-88-2 2-(3-nitrophenoxy)acetic acid 
• 591-27-5 m-Hydroxyaniline 
• 7439-89-6 iron 
• 554-84-7 meta-nitrophenol 
• 19962-06-2 tert-butyl 3-hydroxyphenylcarbamate 
• 170856-29-8 Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate 

Downstream Products

• 62877-06-9 (3-aminophenoxy)acetamide 
• 170855-82-0 1,5-Bis-(cyclopropylcarbonylmethyl)-3-(N'-(m-(carboethoxymethoxy)phenyl)ureido)-1H-1,5-benzodiazepine-2,4(3H,5H)-dione 
• 205694-18-4 ethyl 2-(3-{N-[2-(N-tert-butoxycarbonylamino)acetyl]amino}phenoxy)acetate 
• 1093799-15-5 C₂₆H₃₄N₆O₆ 
• 50963-77-4 3-(2-hydroxyethoxy)aniline 
• 1202760-24-4 C₂₅H₂₈FN₅O₅ 
• 1257341-94-8 5,7-dichloro-4-[(3-ethoxycarbonylmethoxyphenylcarbamoyl)-methoxy]-naphthalene-2-carboxylic acid methyl ester 
• 1202760-25-5 C₂₅H₃₀FN₅O₄ 
• 1202757-27-4 N-(3-(5-fluoro-2-(3-(2-hydroxy-2-methylpropoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide 
• 1202760-26-6 C₂₀H₂₂FN₅O₂ 
• 1310744-77-4 (R)-2-(3-(((3-(carboxymethoxy)phenyl)amino)methyl)benzamido)pentanedioic acid 
• 1078736-59-0 (R)-{3-[{2-[3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)butyryl]-3,4-dihydro-2H-pyrazole-3-carbonyl}amino]phenoxy}acetic acid ethyl ester 

Relevant academic research and scientific papers

KIF18A INHIBITORS

Amide compounds of formula (I): and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of Kinesin Motor Protein KIF18A, such as cancer, psoriasis, atopic dermatitis, an autoimmune disorder, or inflammatory bowel disease, and the like.

2,4-Pyrimidinediamine Compounds and Their Uses

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C

The present invention provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.

Structure-based design of a new series of d-glutamic acid based inhibitors of bacterial UDP-N-acetylmuramoyl-l-alanine: D-glutamate ligase (MurD)

MurD ligase is one of the key enzymes participating in the intracellular steps of peptidoglycan biosynthesis and constitutes a viable target in the search for novel antibacterial drugs to combat bacterial drug-resistance. We have designed, synthesized, and evaluated a new series of d-glutamic acid-based Escherichia coli MurD inhibitors incorporating the 5-benzylidenethiazolidin-4- one scaffold. The crystal structure of 16 in the MurD active site has provided a good starting point for the design of structurally optimized inhibitors 73-75 endowed with improved MurD inhibitory potency (IC50 between 3 and 7 μM). Inhibitors 74 and 75 showed weak activity against Gram-positive Staphylococcus aureus and Enterococcus faecalis. Compounds 73-75, with IC 50 values in the low micromolar range, represent the most potent d-Glu-based MurD inhibitors reported to date.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides inhibitors of protein kinases of formula I-a and I-b, pharmaceutically acceptable compositions thereof, and methods of using the same.

ANTIFUNGAL AGENTS

Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

Generation of ligand conformations in continuum solvent consistent with protein active site topology: Application to thrombin

Using the crystal structure of an inhibitor complexed with the serine protease thrombin (PDB code 1UVT) and the functional group definitions contained within the Catalyst software, a representation of the enzyme's active site was produced (structure-based

Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors

A novel series of phenoxyacetic acid derivatives was synthesized based on considerations of the three-dimensional structural similarity of YM022 and RP72540. The gastrin/cholecystokinin (CCK)-B and CCK-A receptor antagonist activities of these compounds were evaluated by investigation of their affinities for human gastrin/CCK-B receptors and human CCK-A receptors, respectively. It was found that N-methyl-N-phenyl-2-[2-[N-(N-methyl-N- phenyl-carbamoylmethyl)-N-[2-[3-(3- methylphenyl)ureido]acetyl]amino]phenoxy]acetamide (20k, DZ-3514) exhibited high affinity for gastrin/CCK-B receptors and high selectivity over CCK-A receptors.

Benzodiazepine derivative

A benzodiazepine derivative of the formula (I): STR1 wherein R 1 is a bond, --CH 2 --, --CH 2 O--, --SCH 2 -- or a group of the formula: STR2 R 2 is a lower alkyl, --COOR 5, --CONH(CH 2) n COOR 5, --CONHSO 2 R 5, --SO 2 NHCOR 5, or an optionally substituted heterocyclic group (R 5 is a hydrogen atom, lower alkyl or benzyl and n is an integer of 1 to 5); R 3 is a bond, --CO-- or --CONH--; and R 4 is an optionally substituted heterocyclic group, optionally substituted lower alkyl, optionally substituted lower cycloalkyl, optionally substituted aryl, or lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, which has a high affinity for gastrin receptors and/or CCK-B receptors but not for CCK-A receptors, and is useful for treating diseases associated with gastrin receptors and/or CCK-B receptors without inducing the side effects associated with CCK-A receptors.